GlassScriptPhysician profile
Julian E Safran
NPI 1861407744
$6,063.97
in general payments reported to CMS, 2019-2025
35 companies · $1,054 in 2025
The $1,054 reported for 2025 was more than what 84% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $471 · 2021: $99.74 · 2022: $1,701 · 2023: $1,055 · 2024: $1,180 · 2025: $1,054.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $1,194.24 | 2022 | |
| Sumitomo Pharma America, INC. | $538.99 | 2023-2025 | Myfembree |
| Astellas Pharma US INC | $478.03 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $463.62 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Organon LLC | $296.14 | 2023-2025 | Nexplanon |
| Myriad Women'S Health, INC. | $257.37 | 2023 | Myrisk |
| Coopersurgical, INC. | $244.05 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $235.53 | 2019-2025 | Intrarosa, Femring, Femlyv |
| Sage Therapeutics, LLC | $226.23 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $211.67 | 2019-2025 | |
| Therapeuticsmd, INC. | $194.89 | 2019-2022 | |
| Renovia INC | $187.19 | 2019-2020 | |
| Exeltis, USA INC. | $182.39 | 2020-2025 | Slynd |
| Viiv Healthcare Company | $168.69 | 2024-2025 | Apretude |
| Daiichi Sankyo INC. | $159.17 | 2020-2024 | Injectafer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $137.15 | 2019-2025 | |
| Exact Sciences Corporation | $111.25 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mayne Pharma Commercial LLC | $99.84 | 2021-2023 | |
| Avion Pharmaceuticals | $90.64 | 2019-2020 | |
| Shield Therapeutics INC | $79.75 | 2025 | |
| Aspira Women'S Health INC | $77.68 | 2022-2024 | Ova1 |
| Myovant Sciences INC. | $73.69 | 2022 | |
| Hologic Sales and Service, LLC | $63.09 | 2019-2024 | Aptima |
| Seqirus USA INC | $48.09 | 2025 | Fluad, Flucelvax |
| Duchesnay USA Incorporated | $38.64 | 2019 | |
| Mylan Pharmaceuticals INC. | $32.94 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $31.34 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $26.62 | 2022 | |
| Merck Sharp & Dohme LLC | $25.03 | 2025 | Gardasil 9 |
| Dexcom, INC. | $23.60 | 2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $21.51 | 2024 | Bd Max System, Bd Max Instrument |
| Optumhealth Care Solutions, LLC | $17.23 | 2024 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Ferring Pharmaceuticals INC. | $15.21 | 2020 | |
| Sanofi Pasteur INC. | $12.47 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Safran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.